产品说明书
PF-06751979
 |
同义名 : | - |
| CAS号 : | 1818339-66-0 | |
| 货号 : | A294210 | |
| 分子式 : | C18H19F2N5O3S2 | |
| 纯度 : | 99%+ | |
| 分子量 : | 455.502 | |
| MDL号 : | MFCD31657420 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 145 mg/mL(318.33 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO 无水乙醇: 50 mg/mL(109.77 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | PF-06751979 is a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 7.3 nM in BACE1 binding assay. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02793232 | Healthy Subjects | Phase 1 | Completed | - | Belgium ... 展开 >> Pfizer Clinical Research Unit Brussels, Belgium, B-1070 收起 << |
| NCT02793232 | - | Completed | - | - | |
| NCT02509117 | Healthy Subjects | Phase 1 | Completed | - | United States, California ... 展开 >> California Clinical Trials Medical Group, Inc Glendale, California, United States, 91206 Glendale Adventist Medical Center Glendale, California, United States, 91206 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.20mL 0.44mL 0.22mL |
10.98mL 2.20mL 1.10mL |
21.95mL 4.39mL 2.20mL |
